share_log

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts

評估ionis pharmaceuticals:來自6名金融分析師的見解。
Benzinga ·  06/27 09:00
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.
最近三個月,有6位分析師對Ionis Pharmaceuticals(NASDAQ:IONS)進行了評估,表達了看好和看淡的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級,展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.0, a high estimate of $82.00, and a low estimate of $53.00. A 0.61% drop is evident in the current average compared to the previous average price target of $65.40.
分析師提出的12個月價格目標提供了以下見解:平均目標爲65.0美元,最高估值爲82.00美元,最低估值爲53.00美元。與先前的平均目標價格65.40美元相比,當前平均價格有0.61%的下降趨勢。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析:詳細分析
The analysis of recent analyst actions...
最近的分析師...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論